Amneal Pharmaceuticals (AMRX) vs Kiniksa Pharmaceuticals International (KNSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kiniksa Pharmaceuticals International (KNSA) has outperformed Amneal Pharmaceuticals (AMRX) over the past year, gaining 104.5% versus a gain of 89.7%. Over five years, KNSA leads with a +580.9% price change compared with +248.4% for AMRX. Amneal Pharmaceuticals is the larger company by market cap ($6.84 billion vs $6.08 billion), about 1.1 times the size, while Kiniksa Pharmaceuticals International is growing revenue faster (+60.1% vs +8.0%).
On valuation, Amneal Pharmaceuticals trades at a lower forward P/E (16.5x vs 48.2x for Kiniksa Pharmaceuticals International). Kiniksa Pharmaceuticals International converts more of its revenue into profit, with a net margin of 8.7% versus 2.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRX | KNSA |
|---|---|---|
| Share price | $19.65 | $77.96 |
| Market cap | $6.84B | $6.08B |
| 1-day change | -3.18% | +1.13% |
| YTD return | +55.95% | +88.99% |
| 1-year return | +89.67% | +104.51% |
| 5-year return | +248.40% | +580.87% |
| P/E ratio (TTM) | 40.10 | 78.75 |
| Forward P/E | 16.48 | 48.20 |
| EPS (TTM) | $0.49 | $0.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.02B | $677.56M |
| Revenue growth (YoY) | +8.05% | +60.09% |
| Net income (latest FY) | $72.06M | $59.01M |
| Gross margin | 36.88% | 88.54% |
| Operating margin | 13.05% | 11.40% |
| Net margin | 2.39% | 8.71% |
| 52-week high | $21.18 | $82.94 |
| 52-week low | $9.56 | $35.20 |
| Distance from 52-week high | -7.20% | -6.00% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +15.57% | +25.71% |
| Average volume | 2.22M | 589.58K |
| Shares outstanding | 348.30M | 48.29M |
| Employees | 8,700 | 366 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KNSA has outperformed AMRX by 14.8 percentage points over the past year.
- Kiniksa Pharmaceuticals International trades at a higher earnings multiple (78.7x vs 40.1x trailing P/E).
- Kiniksa Pharmaceuticals International is more profitable, keeping 8.7 cents of every revenue dollar as net income versus 2.4 cents for Amneal Pharmaceuticals.
- Kiniksa Pharmaceuticals International grew revenue faster in its latest fiscal year (+60.09% vs +8.05%).
About Amneal Pharmaceuticals
AMRX stock →Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,700 employees
About Kiniksa Pharmaceuticals International
KNSA stock →Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 366 employees
AMRX vs KNSA FAQ
Which is bigger, Amneal Pharmaceuticals or Kiniksa Pharmaceuticals International?
Amneal Pharmaceuticals (AMRX) is larger, with a market capitalization of $6.84B compared with $6.08B for Kiniksa Pharmaceuticals International (KNSA).
Which stock has performed better over the past year, AMRX or KNSA?
KNSA returned +104.51% over the past 12 months, compared with +89.67% for AMRX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, AMRX or KNSA?
AMRX has the lower trailing P/E at 40.1, versus 78.7 for KNSA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Amneal Pharmaceuticals and Kiniksa Pharmaceuticals International in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.